tiprankstipranks
Advertisement
Advertisement

HK:2105 Stock Latest News

Laekna Advances Obesity Candidate LAE102 With Positive Phase I Data
Company AnnouncementsLaekna Advances Obesity Candidate LAE102 With Positive Phase I Data
22d ago
2105
Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102
PremiumCompany Announcements
Laekna Announces Positive Phase I Results for Obesity-Targeted Antibody LAE102
1M ago
2105
Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
Laekna Sets March 2026 Board Meeting to Approve 2025 Annual Results
1M ago
2105
Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118
PremiumCompany Announcements
Laekna Wins FDA Acceptance of IND for New PI3Kα Inhibitor LAE118
3M ago
2105
Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103
PremiumCompany Announcements
Laekna Doses First Subject in Phase I Trial of Metabolic Drug Candidate LAE103
3M ago
2105
Laekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102
PremiumCompany AnnouncementsLaekna Doses First Patient in Phase I Multiple-Dose Expansion Study of Obesity Drug LAE102
4M ago
2105
Laekna Completes Enrollment for Phase III Breast Cancer Trial
Premium
Company Announcements
Laekna Completes Enrollment for Phase III Breast Cancer Trial
4M ago
2105
Laekna, Inc. Updates Nomination and Governance Committee
Premium
Company Announcements
Laekna, Inc. Updates Nomination and Governance Committee
4M ago
2105
Laekna, Inc. Announces Board of Directors and Committee Roles
PremiumCompany Announcements
Laekna, Inc. Announces Board of Directors and Committee Roles
4M ago
2105
Laekna, Inc. Updates Governance Committee Terms
PremiumCompany Announcements
Laekna, Inc. Updates Governance Committee Terms
4M ago
2105
Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China
PremiumCompany Announcements
Laekna, Inc. Partners with Qilu Pharma for Exclusive Licensing of LAE002 in China
5M ago
2105
Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study
PremiumCompany Announcements
Laekna, Inc. Advances Breast Cancer Treatment with Promising Clinical Study
5M ago
2105
Laekna, Inc. Advances Obesity Treatment with LAE102 Study
PremiumCompany AnnouncementsLaekna, Inc. Advances Obesity Treatment with LAE102 Study
5M ago
2105
Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment
Premium
Company Announcements
Laekna, Inc. Reports Positive Phase I Results for Obesity Treatment
6M ago
2105
Laekna, Inc. Completes Successful Share Placement to Boost R&D
Premium
Company Announcements
Laekna, Inc. Completes Successful Share Placement to Boost R&D
7M ago
2105
Laekna, Inc. Advances Obesity Treatment with Promising Clinical Trial Results
PremiumCompany Announcements
Laekna, Inc. Advances Obesity Treatment with Promising Clinical Trial Results
8M ago
2105
Laekna, Inc. Secures FDA Approval for New Metabolic Disease Therapy
PremiumCompany Announcements
Laekna, Inc. Secures FDA Approval for New Metabolic Disease Therapy
8M ago
2105
Laekna, Inc. Schedules Board Meeting to Review Interim Results
PremiumCompany Announcements
Laekna, Inc. Schedules Board Meeting to Review Interim Results
8M ago
2105
Laekna, Inc. Advances LAE103 with FDA Application
PremiumCompany Announcements
Laekna, Inc. Advances LAE103 with FDA Application
9M ago
2105
Laekna, Inc. Unveils Promising Study Results at ADA 2025
PremiumCompany AnnouncementsLaekna, Inc. Unveils Promising Study Results at ADA 2025
10M ago
2105
Laekna, Inc. Successfully Concludes Annual General Meeting with All Resolutions Passed
Premium
Company Announcements
Laekna, Inc. Successfully Concludes Annual General Meeting with All Resolutions Passed
10M ago
2105
Laekna, Inc. Announces Annual General Meeting and Key Resolutions
Premium
Company Announcements
Laekna, Inc. Announces Annual General Meeting and Key Resolutions
11M ago
2105

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >